Corcept Therapeutics Incorporated (CORT) Set to Announce Quarterly Earnings on Monday
Corcept Therapeutics Incorporated (NASDAQ:CORT) is scheduled to be announcing its earnings results after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.09 per share for the quarter.
Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. The firm had revenue of $35.56 million for the quarter, compared to the consensus estimate of $31.37 million. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The business’s revenue was up 80.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.01 earnings per share. On average, analysts expect Corcept Therapeutics to post $0.42 EPS for the current fiscal year and $0.70 EPS for the next fiscal year.
Corcept Therapeutics Incorporated (NASDAQ:CORT) opened at 18.39 on Monday. The company has a market cap of $2.09 billion, a P/E ratio of 91.49 and a beta of 2.12. The stock has a 50 day moving average of $18.50 and a 200 day moving average of $13.58. Corcept Therapeutics Incorporated has a 52 week low of $6.68 and a 52 week high of $20.77.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/corcept-therapeutics-incorporated-cort-set-to-announce-quarterly-earnings-on-monday.html.
A number of brokerages have recently issued reports on CORT. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Corcept Therapeutics in a research report on Wednesday, October 11th. Stifel Nicolaus began coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They issued a “buy” rating and a $20.00 price objective on the stock. BidaskClub raised shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 18th. Finally, Ladenburg Thalmann Financial Services set a $20.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $16.17.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.